Replies to post #156902 on Biotech Values

[jq1234]

Celltrion shares jump on reports of bid interests from Roche, Teva, AstraZeneca

Jan 8 (Reuters) - Celltrion Inc shares jumped by 9.7 percent on Wednesday after South Korean media such as online news outlet Edaily reported that Roche Holding AG , Teva Pharmaceutical Industries Ltd and AstraZeneca Plc were among parties in talks to acquire the biotech firm.

Celltrion, the biggest firm in the country's second-tier KOSDAQ share market, said last week that its largest shareholder is in talks with interested parties to sell a controlling stake in the company.

A Celltrion spokesman declined to comment.

http://uk.reuters.com/article/2014/01/08/celltrion-sale-idUKL3N0KI0MD20140108

[DewDiligence]

TEVA, Celltrion ink FoB collaboration for Rituxan/Herceptin in US/Canada:

http://finance.yahoo.com/news/teva-celltrion-announce-exclusive-biosimilar-120000044.html

This is essentially a booby price for TEVA, who has been actively searching for a global FoB partner. Celltrion’s FoB programs for Rituxan and Herceptin were returned by PFE in 2015 as a consequence of PFE’s merger with HSP (http://www.fiercebiotech.com/r-d/pfizer-cuts-some-biosimilar-ties-celltrion-after-its-17b-hospira-deal ).